Get started
Author

Annie Kennedy

Observed names: A. Kennedy, Kennedy, Annie
ORCID: 0000-0002-0987-675X
Observed ORCID: 0000-0002-0987-675X
OpenAlex ID: A5026639517
Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan
2018 · David J Birnkrant, Katharine Bushby, et al. · The Lancet Neurology · 473
The national economic burden of rare disease in the United States in 2019
2022 · Grace Yang, Inna Cintina, et al. · Orphanet Journal of Rare Diseases · 165
PDF
Cost of illness for neuromuscular diseases in the United States
2013 · Jane Larkindale, Wenya Yang, et al. · Muscle & Nerve · 160
PDF
A Transition Toolkit for Duchenne Muscular Dystrophy
2018 · Christina J. Trout, Laura E. Case, et al. · PEDIATRICS · 42
The sixth international RASopathies symposium: Precision medicine—From promise to practice
2019 · Karen W. Gripp, Lisa Schill, et al. · American Journal of Medical Genetics Part A · 40
PDF
Newborn screening for Duchenne muscular dystrophy: A two‐year pilot study
2023 · Norma P. Tavakoli, Dorota Gruber, et al. · Annals of Clinical and Translational Neurology · 35
PDF
Duchenne Muscular Dystrophy Newborn Screening: Evaluation of a New GSP® Neonatal Creatine Kinase-MM Kit in a US and Danish Population
2019 · Anne Timonen, Michele Lloyd-Puryear, et al. · International Journal of Neonatal Screening · 32
PDF
Stakeholder-Engaged Derivation of Patient-Informed Value Elements
2020 · Susan dosReis, Beverly Butler, et al. · Patient · 31
PDF
Patient-Centered Core Impact Sets: What They are and Why We Need Them
2022 · Eleanor M. Perfetto, Elisabeth M. Oehrlein, et al. · Patient · 28
PDF
Clinical Follow-Up for Duchenne Muscular Dystrophy Newborn Screening: A Proposal
2016 · Jennifer M. Kwon, Hoda Z. Abdel-Hamid, et al. · Muscle & Nerve · 26
1st Workshop on Upper-Extremity Assistive Technology for People with Duchenne: State of the art, emerging avenues, and challenges
2016 · Arjen Bergsma, Joan Lobo-Prat, et al. · Neuromuscular Disorders · 22
PDF
Are we prepared to deliver gene‐targeted therapies for rare diseases?
2023 · Timothy W. Yu, Stephen F. Kingsmore, et al. · American Journal of Medical Genetics Part C Seminars in Medical Genetics · 19
PDF
A Roadmap to Newborn Screening for Duchenne Muscular Dystrophy
2017 · Samiah Al-Zaidy, Michele Lloyd-Puryear, et al. · International Journal of Neonatal Screening · 17
PDF
Health Care Transition Experiences of Males with Childhood-onset Duchenne and Becker Muscular Dystrophy: Findings from the Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet) Health Care Transitions and Other Life Experiences Survey
2018 · Pangaja Paramsothy, Adrienne R. Herron, et al. · PLoS Currents · 15
The Economic Burden Of Rare Diseases: Quantifying The Sizeable Collective Burden And Offering Solutions
2022 · Sheldon Garrison, Annie Kennedy, et al. · Forefront Group · 10
Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy Therapies
2024 · Ryan Fischer, Pat Furlong, et al. · Journal of Multidisciplinary Healthcare · 8
PDF
The Early Care (0–3 Years) In Duchenne Muscular Dystrophy Meeting Report
2024 · Niki Armstrong, Susan Apkon, et al. · Journal of Neuromuscular Diseases · 7
PDF
Common Challenges and Identified Solutions for State Newborn Screening Programs during COVID-19 Pandemic
2022 · Dylan Simon, Elizabeth Broadbridge, et al. · International Journal of Neonatal Screening · 7
PDF
Duchenne Muscular Dystrophy Newborn Screening, a Case Study for Examining Ethical and Legal Issues for Pilots for Emerging Disorders: Considerations and Recommendations
2018 · Michele Lloyd-Puryear, Thomas Crawford, et al. · International Journal of Neonatal Screening · 7
PDF
Promoting meaningful clinical trial outcome measures for Duchenne muscular dystrophy
2016 · H. Peay, A. Kennedy, et al. · Neuromuscular Disorders · 6
A Foundation for Patient-Centered Core Impact Sets: Key Learnings from Past and Existing Approaches
2023 · Eleanor M. Perfetto, T. Rosie Love, et al. · Patient · 5
Expediting treatments in the 21st century: orphan drugs and accelerated approvals
2024 · Reuben Domike, G. K. Raju, et al. · Orphanet Journal of Rare Diseases · 4
PDF
Data Sharing Goals for Nonprofit Funders of Clinical Trials
2020 · Timothy Coetzee, Mad Price Ball, et al. · Journal of Participatory Medicine · 4
PDF
Cost of illness for neuromuscular diseases in the U.S
2014 · Jane Larkindale, Wenya Yang, et al. · 2
Pediatric-onset rare disease therapy pipeline yields hope for some and gaps for many: 10-year projection of approvals, treated patients, and list price revenues
2025 · Colin M. Young, Sharon E. Phares, et al. · Journal of Managed Care & Specialty Pharmacy · 1
Works count: 38
Citation count: 1,168
H-index: 14
I10-index: 15
Year
Topic
Type